Intergroup IM. 35 | Real-world outcomes of targeted therapy in stage IV melanoma after relapse on adjuvant dabrafenib and trametinib: insights from a single-center cohort: Rossella Villani, Chiara Bungaro, Anna Cecere, Ileana De Roma, Sabino Strippoli, Michele Guida | Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy. Dermatol Reports [Internet]. 2025 Dec. 11 [cited 2026 Jul. 26];. Available from: https://journals.pagepress.net/dr/article/view/10777